Merck Launches Biosimilars Clarified, a New Online Educational Resource about Biosimilar Medicines for Patients and the Healthcare Community
October 14, 2016 7:30 am ET
Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the launch of Biosimilars Clarified (www.merckclarifiesbiosimilars.com),
a new educational website for patients, caregivers and the healthcare
community that is designed to provide clear, concise and straightforward
information about biosimilar medicines.
Biosimilars are a type of biological product that are approved by the
U.S. Food and Drug Administration (FDA) because they are highly similar
to an already FDA-approved biological product, known as the originator
biologic or reference product, and have been shown to have no clinically
meaningful differences in terms of the safety, purity and potency of the
“Biosimilars can offer alternative treatment options, and have the
potential to help reduce healthcare spending and increase access to
important biologic medicines,” said Dora Bibila, general manager, Merck
Biosimilars. “At Merck, we want to provide educational resources for
patients and caregivers to help them get the information they want and
need. We believe the more patients know, the more they can be in charge
of their health – Biosimilars Clarified is designed to help
answer their questions about biosimilars.”
Biosimilars Clarified offers a host of informative features in a
simple, easy-to-use question-and-answer format. The website was
developed to provide patients, their caregivers, healthcare
professionals and others clarification on such topics as:
- What are biologic medicines?
- Biosimilars – are they safe and effective?
- The value of biosimilars and increasing access to treatment.
- The availability of support programs for patients taking biosimilars.
“Merck is one of the largest pharmaceutical companies in the world
today, and we have a long-standing commitment to supporting patients and
the healthcare community. We are continuing that commitment with Merck
Biosimilars,” Bibila said.
For 125 years, Merck has been a global health care leader working to
help the world be well. Merck is known as MSD outside the United States
and Canada. Through our prescription medicines, vaccines, biologic
therapies, and animal health products, we work with customers and
operate in more than 140 countries to deliver innovative health
solutions. We also demonstrate our commitment to increasing access to
health care through far-reaching policies, programs and partnerships.
For more information, visit www.merck.com
and connect with us on Twitter,
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the
“company”) includes “forward-looking statements” within the meaning of
the safe harbor provisions of the U.S. Private Securities Litigation
Reform Act of 1995. These statements are based upon the current beliefs
and expectations of the company’s management and are subject to
significant risks and uncertainties. If underlying assumptions prove
inaccurate or risks or uncertainties materialize, actual results may
differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest
rate and currency exchange rate fluctuations; the impact of
pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care cost
containment; technological advances, new products and patents attained
by competitors; challenges inherent in new product development,
including obtaining regulatory approval; the company’s ability to
accurately predict future market conditions; manufacturing difficulties
or delays; financial instability of international economies and
sovereign risk; dependence on the effectiveness of the company’s patents
and other protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause results
to differ materially from those described in the forward-looking
statements can be found in the company’s 2015 Annual Report on Form 10-K
and the company’s other filings with the Securities and Exchange
Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
Robert Consalvo, 908-236-1127